 Fully funded by the Canadian Institute of Health Research CIHR, this multi-site clinical trial will take place at Torontos University Health Network UHN and Braxias CRTCE Research Clinic Largest study of its kind with IV Ketamine to be conducted in people living with bipolar disorder, a leading cause of treatment-resistant depression and suicidality Research funding award highlights Braxias national and international leadership in the research and development of novel IV ketamine treatments for brain disorders TORONTO, June 17, 2021 PRNewswire - Braxia Scientific Corp. Braxia, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders is pleased to announce that Dr. Josh Rosenblat, Braxia Scientifics Chief Medical and Science Officer, has been awarded and received funding by the Canadian Institute of Health Research CIHR, of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. The fully funded study, representing the largest registered trial of its kind in the world, will investigate the use, safety and efficacy of repeated doses of intravenous IV Ketamine in patients with Bipolar Depression. 